Review



pac1 receptor antagonist pacap(6–38)  (Bachem)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Bachem pac1 receptor antagonist pacap(6–38)
    Pac1 Receptor Antagonist Pacap(6–38), supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pac1+receptor+antagonist+pacap(6%E2%80%9338)/pac1+receptor+antagonist+pacap+6+38/pmc06339595-93-6-10
    Average 90 stars, based on 1 article reviews
    pac1 receptor antagonist pacap(6–38) - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    Cell Culture:

    Article Title: Pituitary Adenylate Cyclase-Activating Polypeptide Inhibits Transforming Growth Factor-?1-Induced Apoptosis in a Human Pituitary Adenoma Cell Line
    Article Snippet: The following reagents were used in cell culture studies, and the final concentration was obtained after preliminary titration experiments: porcine TGF-β1 (1 × 10 −9 mol/L; R&D Systems, Minneapolis, MN); PACAP38 and PACAP27-NH2 (2.5 × 16 −7 mol/L; Peninsula Lab, Belmont, CA); PACAP 6–38 (PACAP type I receptor antagonist) and ( p -chloro- d -Phe, 6 Leu 17 )-VIP (PACAP type II receptor antagonist) (10 −6 mol/L; Bachem, Torrance, CA); phorbol 12-myristate 13-acetate (PMA) (10 −7 mol/L); and forskolin (10 −6 mol/L) (Sigma Chemical Co., St. Louis, MO).

    Concentration Assay:

    Article Title: Pituitary Adenylate Cyclase-Activating Polypeptide Inhibits Transforming Growth Factor-?1-Induced Apoptosis in a Human Pituitary Adenoma Cell Line
    Article Snippet: The following reagents were used in cell culture studies, and the final concentration was obtained after preliminary titration experiments: porcine TGF-β1 (1 × 10 −9 mol/L; R&D Systems, Minneapolis, MN); PACAP38 and PACAP27-NH2 (2.5 × 16 −7 mol/L; Peninsula Lab, Belmont, CA); PACAP 6–38 (PACAP type I receptor antagonist) and ( p -chloro- d -Phe, 6 Leu 17 )-VIP (PACAP type II receptor antagonist) (10 −6 mol/L; Bachem, Torrance, CA); phorbol 12-myristate 13-acetate (PMA) (10 −7 mol/L); and forskolin (10 −6 mol/L) (Sigma Chemical Co., St. Louis, MO).

    Titration:

    Article Title: Pituitary Adenylate Cyclase-Activating Polypeptide Inhibits Transforming Growth Factor-?1-Induced Apoptosis in a Human Pituitary Adenoma Cell Line
    Article Snippet: The following reagents were used in cell culture studies, and the final concentration was obtained after preliminary titration experiments: porcine TGF-β1 (1 × 10 −9 mol/L; R&D Systems, Minneapolis, MN); PACAP38 and PACAP27-NH2 (2.5 × 16 −7 mol/L; Peninsula Lab, Belmont, CA); PACAP 6–38 (PACAP type I receptor antagonist) and ( p -chloro- d -Phe, 6 Leu 17 )-VIP (PACAP type II receptor antagonist) (10 −6 mol/L; Bachem, Torrance, CA); phorbol 12-myristate 13-acetate (PMA) (10 −7 mol/L); and forskolin (10 −6 mol/L) (Sigma Chemical Co., St. Louis, MO).

    Hybridization:

    Article Title: Pituitary Adenylate Cyclase-Activating Polypeptide Inhibits Transforming Growth Factor-?1-Induced Apoptosis in a Human Pituitary Adenoma Cell Line
    Article Snippet: The following reagents were used in cell culture studies, and the final concentration was obtained after preliminary titration experiments: porcine TGF-β1 (1 × 10 −9 mol/L; R&D Systems, Minneapolis, MN); PACAP38 and PACAP27-NH2 (2.5 × 16 −7 mol/L; Peninsula Lab, Belmont, CA); PACAP 6–38 (PACAP type I receptor antagonist) and ( p -chloro- d -Phe, 6 Leu 17 )-VIP (PACAP type II receptor antagonist) (10 −6 mol/L; Bachem, Torrance, CA); phorbol 12-myristate 13-acetate (PMA) (10 −7 mol/L); and forskolin (10 −6 mol/L) (Sigma Chemical Co., St. Louis, MO).

    Reverse Transcription Polymerase Chain Reaction:

    Article Title: Pituitary Adenylate Cyclase-Activating Polypeptide Inhibits Transforming Growth Factor-?1-Induced Apoptosis in a Human Pituitary Adenoma Cell Line
    Article Snippet: The following reagents were used in cell culture studies, and the final concentration was obtained after preliminary titration experiments: porcine TGF-β1 (1 × 10 −9 mol/L; R&D Systems, Minneapolis, MN); PACAP38 and PACAP27-NH2 (2.5 × 16 −7 mol/L; Peninsula Lab, Belmont, CA); PACAP 6–38 (PACAP type I receptor antagonist) and ( p -chloro- d -Phe, 6 Leu 17 )-VIP (PACAP type II receptor antagonist) (10 −6 mol/L; Bachem, Torrance, CA); phorbol 12-myristate 13-acetate (PMA) (10 −7 mol/L); and forskolin (10 −6 mol/L) (Sigma Chemical Co., St. Louis, MO).

    Positive Control:

    Article Title: Pituitary Adenylate Cyclase-Activating Polypeptide Inhibits Transforming Growth Factor-?1-Induced Apoptosis in a Human Pituitary Adenoma Cell Line
    Article Snippet: The following reagents were used in cell culture studies, and the final concentration was obtained after preliminary titration experiments: porcine TGF-β1 (1 × 10 −9 mol/L; R&D Systems, Minneapolis, MN); PACAP38 and PACAP27-NH2 (2.5 × 16 −7 mol/L; Peninsula Lab, Belmont, CA); PACAP 6–38 (PACAP type I receptor antagonist) and ( p -chloro- d -Phe, 6 Leu 17 )-VIP (PACAP type II receptor antagonist) (10 −6 mol/L; Bachem, Torrance, CA); phorbol 12-myristate 13-acetate (PMA) (10 −7 mol/L); and forskolin (10 −6 mol/L) (Sigma Chemical Co., St. Louis, MO).

    Negative Control:

    Article Title: Pituitary Adenylate Cyclase-Activating Polypeptide Inhibits Transforming Growth Factor-?1-Induced Apoptosis in a Human Pituitary Adenoma Cell Line
    Article Snippet: The following reagents were used in cell culture studies, and the final concentration was obtained after preliminary titration experiments: porcine TGF-β1 (1 × 10 −9 mol/L; R&D Systems, Minneapolis, MN); PACAP38 and PACAP27-NH2 (2.5 × 16 −7 mol/L; Peninsula Lab, Belmont, CA); PACAP 6–38 (PACAP type I receptor antagonist) and ( p -chloro- d -Phe, 6 Leu 17 )-VIP (PACAP type II receptor antagonist) (10 −6 mol/L; Bachem, Torrance, CA); phorbol 12-myristate 13-acetate (PMA) (10 −7 mol/L); and forskolin (10 −6 mol/L) (Sigma Chemical Co., St. Louis, MO).

    Reverse Transcription:

    Article Title: Pituitary Adenylate Cyclase-Activating Polypeptide Inhibits Transforming Growth Factor-?1-Induced Apoptosis in a Human Pituitary Adenoma Cell Line
    Article Snippet: The following reagents were used in cell culture studies, and the final concentration was obtained after preliminary titration experiments: porcine TGF-β1 (1 × 10 −9 mol/L; R&D Systems, Minneapolis, MN); PACAP38 and PACAP27-NH2 (2.5 × 16 −7 mol/L; Peninsula Lab, Belmont, CA); PACAP 6–38 (PACAP type I receptor antagonist) and ( p -chloro- d -Phe, 6 Leu 17 )-VIP (PACAP type II receptor antagonist) (10 −6 mol/L; Bachem, Torrance, CA); phorbol 12-myristate 13-acetate (PMA) (10 −7 mol/L); and forskolin (10 −6 mol/L) (Sigma Chemical Co., St. Louis, MO).

    Control:

    Article Title: Pituitary Adenylate Cyclase-Activating Polypeptide Inhibits Transforming Growth Factor-?1-Induced Apoptosis in a Human Pituitary Adenoma Cell Line
    Article Snippet: The following reagents were used in cell culture studies, and the final concentration was obtained after preliminary titration experiments: porcine TGF-β1 (1 × 10 −9 mol/L; R&D Systems, Minneapolis, MN); PACAP38 and PACAP27-NH2 (2.5 × 16 −7 mol/L; Peninsula Lab, Belmont, CA); PACAP 6–38 (PACAP type I receptor antagonist) and ( p -chloro- d -Phe, 6 Leu 17 )-VIP (PACAP type II receptor antagonist) (10 −6 mol/L; Bachem, Torrance, CA); phorbol 12-myristate 13-acetate (PMA) (10 −7 mol/L); and forskolin (10 −6 mol/L) (Sigma Chemical Co., St. Louis, MO).

    Staining:

    Article Title: Pituitary Adenylate Cyclase-Activating Polypeptide Inhibits Transforming Growth Factor-?1-Induced Apoptosis in a Human Pituitary Adenoma Cell Line
    Article Snippet: The following reagents were used in cell culture studies, and the final concentration was obtained after preliminary titration experiments: porcine TGF-β1 (1 × 10 −9 mol/L; R&D Systems, Minneapolis, MN); PACAP38 and PACAP27-NH2 (2.5 × 16 −7 mol/L; Peninsula Lab, Belmont, CA); PACAP 6–38 (PACAP type I receptor antagonist) and ( p -chloro- d -Phe, 6 Leu 17 )-VIP (PACAP type II receptor antagonist) (10 −6 mol/L; Bachem, Torrance, CA); phorbol 12-myristate 13-acetate (PMA) (10 −7 mol/L); and forskolin (10 −6 mol/L) (Sigma Chemical Co., St. Louis, MO).

    Western Blot:

    Article Title: Pituitary Adenylate Cyclase-Activating Polypeptide Inhibits Transforming Growth Factor-?1-Induced Apoptosis in a Human Pituitary Adenoma Cell Line
    Article Snippet: The following reagents were used in cell culture studies, and the final concentration was obtained after preliminary titration experiments: porcine TGF-β1 (1 × 10 −9 mol/L; R&D Systems, Minneapolis, MN); PACAP38 and PACAP27-NH2 (2.5 × 16 −7 mol/L; Peninsula Lab, Belmont, CA); PACAP 6–38 (PACAP type I receptor antagonist) and ( p -chloro- d -Phe, 6 Leu 17 )-VIP (PACAP type II receptor antagonist) (10 −6 mol/L; Bachem, Torrance, CA); phorbol 12-myristate 13-acetate (PMA) (10 −7 mol/L); and forskolin (10 −6 mol/L) (Sigma Chemical Co., St. Louis, MO).



    Similar Products

    pac1 receptor antagonist  (Tocris)
    93
    Tocris pac1 receptor antagonist
    Relative pituitary adenylate cyclase-activating peptide receptor <t>(PAC1R)</t> mRNA transcript abundances in the myometrial layer of gilts from the control (CON), saline (SAL) and E. coli ( E. coli ) groups, estimated by real-time PCR. Relative PAC1R mRNA transcript abundances are expressed as the mean ± SEM of ratios in relation to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
    Pac1 Receptor Antagonist, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pac1+receptor+antagonist+pacap(6%E2%80%9338)/PACAP+6-38/pmc09146118-166-6-16
    Average 93 stars, based on 1 article reviews
    pac1 receptor antagonist - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    pac1 vpac2 receptors antagonist pacap 6 38  (Tocris)
    94
    Tocris pac1 vpac2 receptors antagonist pacap 6 38
    Relative pituitary adenylate cyclase-activating peptide receptor <t>(PAC1R)</t> mRNA transcript abundances in the myometrial layer of gilts from the control (CON), saline (SAL) and E. coli ( E. coli ) groups, estimated by real-time PCR. Relative PAC1R mRNA transcript abundances are expressed as the mean ± SEM of ratios in relation to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
    Pac1 Vpac2 Receptors Antagonist Pacap 6 38, supplied by Tocris, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pac1+receptor+antagonist+pacap(6%E2%80%9338)/PACAP+6-38/pm33705861-81-29-34
    Average 94 stars, based on 1 article reviews
    pac1 vpac2 receptors antagonist pacap 6 38 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    pac1 receptor antagonist pacap(6–38)  (Bachem)
    90
    Bachem pac1 receptor antagonist pacap(6–38)
    Relative pituitary adenylate cyclase-activating peptide receptor <t>(PAC1R)</t> mRNA transcript abundances in the myometrial layer of gilts from the control (CON), saline (SAL) and E. coli ( E. coli ) groups, estimated by real-time PCR. Relative PAC1R mRNA transcript abundances are expressed as the mean ± SEM of ratios in relation to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
    Pac1 Receptor Antagonist Pacap(6–38), supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pac1+receptor+antagonist+pacap(6%E2%80%9338)/pac1+receptor+antagonist+pacap+6+38/pmc06339595-93-6-10
    Average 90 stars, based on 1 article reviews
    pac1 receptor antagonist pacap(6–38) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    pac1 receptor antagonist pacap 6-38  (Bachem)
    90
    Bachem pac1 receptor antagonist pacap 6-38
    Relative pituitary adenylate cyclase-activating peptide receptor <t>(PAC1R)</t> mRNA transcript abundances in the myometrial layer of gilts from the control (CON), saline (SAL) and E. coli ( E. coli ) groups, estimated by real-time PCR. Relative PAC1R mRNA transcript abundances are expressed as the mean ± SEM of ratios in relation to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
    Pac1 Receptor Antagonist Pacap 6 38, supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pac1+receptor+antagonist+pacap(6%E2%80%9338)/pac1+receptor+antagonist+pacap+6+38/pmc02896874-165-16-18
    Average 90 stars, based on 1 article reviews
    pac1 receptor antagonist pacap 6-38 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    pacap 6–38 10k6 m selective antagonist of pac1 receptor  (Phoenix Pharmaceuticals)
    90
    Phoenix Pharmaceuticals pacap 6–38 10k6 m selective antagonist of pac1 receptor
    Relative pituitary adenylate cyclase-activating peptide receptor <t>(PAC1R)</t> mRNA transcript abundances in the myometrial layer of gilts from the control (CON), saline (SAL) and E. coli ( E. coli ) groups, estimated by real-time PCR. Relative PAC1R mRNA transcript abundances are expressed as the mean ± SEM of ratios in relation to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
    Pacap 6–38 10k6 M Selective Antagonist Of Pac1 Receptor, supplied by Phoenix Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pac1+receptor+antagonist+pacap(6%E2%80%9338)/pacap+6+38+10k6+m+selective+antagonist+of+pac1+receptor/10__1677_slash_joe___07___0127-90-37-32
    Average 90 stars, based on 1 article reviews
    pacap 6–38 10k6 m selective antagonist of pac1 receptor - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    pac1 and vpac2 receptor antagonist pacap(6-38)  (American Peptide Company Inc)
    90
    American Peptide Company Inc pac1 and vpac2 receptor antagonist pacap(6-38)
    Relative pituitary adenylate cyclase-activating peptide receptor <t>(PAC1R)</t> mRNA transcript abundances in the myometrial layer of gilts from the control (CON), saline (SAL) and E. coli ( E. coli ) groups, estimated by real-time PCR. Relative PAC1R mRNA transcript abundances are expressed as the mean ± SEM of ratios in relation to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
    Pac1 And Vpac2 Receptor Antagonist Pacap(6 38), supplied by American Peptide Company Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pac1+receptor+antagonist+pacap(6%E2%80%9338)/pac1+and+vpac2+receptor+antagonist+pacap+6+38+/10__1158_slash_0008___5472__can___05___2809-58-1-10
    Average 90 stars, based on 1 article reviews
    pac1 and vpac2 receptor antagonist pacap(6-38) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    pac1 receptor antagonist pacap-(6–38)  (Peninsula Laboratories)
    90
    Peninsula Laboratories pac1 receptor antagonist pacap-(6–38)
    Relative pituitary adenylate cyclase-activating peptide receptor <t>(PAC1R)</t> mRNA transcript abundances in the myometrial layer of gilts from the control (CON), saline (SAL) and E. coli ( E. coli ) groups, estimated by real-time PCR. Relative PAC1R mRNA transcript abundances are expressed as the mean ± SEM of ratios in relation to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
    Pac1 Receptor Antagonist Pacap (6–38), supplied by Peninsula Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pac1+receptor+antagonist+pacap(6%E2%80%9338)/pac1+antagonist+pacap6+38/pm12050216-67-27-12
    Average 90 stars, based on 1 article reviews
    pac1 receptor antagonist pacap-(6–38) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Relative pituitary adenylate cyclase-activating peptide receptor (PAC1R) mRNA transcript abundances in the myometrial layer of gilts from the control (CON), saline (SAL) and E. coli ( E. coli ) groups, estimated by real-time PCR. Relative PAC1R mRNA transcript abundances are expressed as the mean ± SEM of ratios in relation to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

    Journal: International Journal of Molecular Sciences

    Article Title: Investigation of the Role of Pituitary Adenylate Cyclase-Activating Peptide (PACAP) and Its Type 1 (PAC1) Receptor in Uterine Contractility during Endometritis in Pigs

    doi: 10.3390/ijms23105467

    Figure Lengend Snippet: Relative pituitary adenylate cyclase-activating peptide receptor (PAC1R) mRNA transcript abundances in the myometrial layer of gilts from the control (CON), saline (SAL) and E. coli ( E. coli ) groups, estimated by real-time PCR. Relative PAC1R mRNA transcript abundances are expressed as the mean ± SEM of ratios in relation to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

    Article Snippet: The strips were then treated with PAC1 receptor antagonist (dose: 10 −6 M, cat. no. 3236, Tocris) for 2 min, and PACAP (doses as given above) was then administered.

    Techniques: Control, Saline, Real-time Polymerase Chain Reaction

    Relative pituitary adenylate cyclase-activating peptide receptor (PAC1R) protein abundances in the myometrial layer of gilts from the control (CON), saline (SAL) and E. coli ( E. coli ) groups, estimated by Western blot analysis. The relative PAC1R protein abundances are expressed as the mean ± SEM of ratios in relation to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The blot with representative bands for each group is presented in . * p < 0.05, *** p < 0.001 compared between groups.

    Journal: International Journal of Molecular Sciences

    Article Title: Investigation of the Role of Pituitary Adenylate Cyclase-Activating Peptide (PACAP) and Its Type 1 (PAC1) Receptor in Uterine Contractility during Endometritis in Pigs

    doi: 10.3390/ijms23105467

    Figure Lengend Snippet: Relative pituitary adenylate cyclase-activating peptide receptor (PAC1R) protein abundances in the myometrial layer of gilts from the control (CON), saline (SAL) and E. coli ( E. coli ) groups, estimated by Western blot analysis. The relative PAC1R protein abundances are expressed as the mean ± SEM of ratios in relation to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The blot with representative bands for each group is presented in . * p < 0.05, *** p < 0.001 compared between groups.

    Article Snippet: The strips were then treated with PAC1 receptor antagonist (dose: 10 −6 M, cat. no. 3236, Tocris) for 2 min, and PACAP (doses as given above) was then administered.

    Techniques: Control, Saline, Western Blot

    Representative pictures show pituitary adenylate cyclase-activating peptide receptor (PAC1R) immunostaining in the myometrial layer of gilts from the control (CON), saline (SAL) and E. coli ( E. coli ) groups. Positive immunoreaction to PAC1R is visible in muscle cells and arteries (endothelium, muscle layer) of the myometrium of the control ( A ), saline-injected ( B ) and inflamed ( C ) uteri. Negative control (NC) for PAC1R ( D ) was obtained by omitting the primary antibody. MMC—myometrial muscle cells; A—artery. The scale bar of each image is 50 µm in length.

    Journal: International Journal of Molecular Sciences

    Article Title: Investigation of the Role of Pituitary Adenylate Cyclase-Activating Peptide (PACAP) and Its Type 1 (PAC1) Receptor in Uterine Contractility during Endometritis in Pigs

    doi: 10.3390/ijms23105467

    Figure Lengend Snippet: Representative pictures show pituitary adenylate cyclase-activating peptide receptor (PAC1R) immunostaining in the myometrial layer of gilts from the control (CON), saline (SAL) and E. coli ( E. coli ) groups. Positive immunoreaction to PAC1R is visible in muscle cells and arteries (endothelium, muscle layer) of the myometrium of the control ( A ), saline-injected ( B ) and inflamed ( C ) uteri. Negative control (NC) for PAC1R ( D ) was obtained by omitting the primary antibody. MMC—myometrial muscle cells; A—artery. The scale bar of each image is 50 µm in length.

    Article Snippet: The strips were then treated with PAC1 receptor antagonist (dose: 10 −6 M, cat. no. 3236, Tocris) for 2 min, and PACAP (doses as given above) was then administered.

    Techniques: Immunostaining, Control, Saline, Injection, Negative Control

    Influence of pituitary adenylate cyclase-activating peptide (PACAP) alone ( A , C ) and PACAP receptor (PAC1R) antagonist with PACAP ( B , D ) on the contractile amplitude in the myometrium ( A , B ) and endometrium/myometrium ( C , D ) strips of gilts from the CON (grey bars), SAL (hatched bars) and E. coli (black bars) groups. Results were calculated for five gilts in each group. The actions of the antagonist (a dose of 10 − 6 M) and particular PACAP doses are depicted as percentage (mean ± SEM) changes from the basal (pre-treatment period) amplitude taken as 100% (horizontal lines). * p < 0.05, ** p < 0.01, *** p < 0.001 compared to the basal value in each group; A p < 0.05, AA p <0.01, AAA p <0.001 between the CON and E. coli groups for the same treatment; BB p < 0.01, BBB p < 0.001 between the SAL and E. coli groups for the same treatment; C p < 0.05 between the CON and SAL groups for the same treatment; # p <0.05, ## p < 0.01, ### p < 0.001 between the antagonist with PACAP action versus PACAP action alone for the same group/tissue/PACAP dose.

    Journal: International Journal of Molecular Sciences

    Article Title: Investigation of the Role of Pituitary Adenylate Cyclase-Activating Peptide (PACAP) and Its Type 1 (PAC1) Receptor in Uterine Contractility during Endometritis in Pigs

    doi: 10.3390/ijms23105467

    Figure Lengend Snippet: Influence of pituitary adenylate cyclase-activating peptide (PACAP) alone ( A , C ) and PACAP receptor (PAC1R) antagonist with PACAP ( B , D ) on the contractile amplitude in the myometrium ( A , B ) and endometrium/myometrium ( C , D ) strips of gilts from the CON (grey bars), SAL (hatched bars) and E. coli (black bars) groups. Results were calculated for five gilts in each group. The actions of the antagonist (a dose of 10 − 6 M) and particular PACAP doses are depicted as percentage (mean ± SEM) changes from the basal (pre-treatment period) amplitude taken as 100% (horizontal lines). * p < 0.05, ** p < 0.01, *** p < 0.001 compared to the basal value in each group; A p < 0.05, AA p <0.01, AAA p <0.001 between the CON and E. coli groups for the same treatment; BB p < 0.01, BBB p < 0.001 between the SAL and E. coli groups for the same treatment; C p < 0.05 between the CON and SAL groups for the same treatment; # p <0.05, ## p < 0.01, ### p < 0.001 between the antagonist with PACAP action versus PACAP action alone for the same group/tissue/PACAP dose.

    Article Snippet: The strips were then treated with PAC1 receptor antagonist (dose: 10 −6 M, cat. no. 3236, Tocris) for 2 min, and PACAP (doses as given above) was then administered.

    Techniques:

    Influence of pituitary adenylate cyclase-activating peptide (PACAP) alone ( A , C ) and PACAP receptor (PAC1R) antagonist with PACAP ( B , D ) on the contractile frequency in the myometria ( A , B ) and endometrium/myometrium ( C , D ) strips of gilts from the CON (grey bars), SAL (hatched bars) and E. coli (black bars) groups. Results were calculated for five gilts in each group. The actions of the antagonist (a dose of 10 − 6 M) and particular PACAP doses are depicted as the percentage (mean ± SEM) change from the basal (pre-treatment period) frequency, taken as 100% (horizontal lines). * p < 0.05, ** p < 0.01, *** p < 0.001 compared to the basal value in each group; A p < 0.05, AAA p < 0.001 compared between the CON and E. coli groups for the same treatment; B p < 0.05, BBB p < 0.001 compared between the SAL and E. coli groups for the same treatment; # p < 0.05, ## p < 0.01, ### p < 0.001 compared between the antagonist with PACAP action versus PACAP action alone for the same group/tissue/PACAP dose.

    Journal: International Journal of Molecular Sciences

    Article Title: Investigation of the Role of Pituitary Adenylate Cyclase-Activating Peptide (PACAP) and Its Type 1 (PAC1) Receptor in Uterine Contractility during Endometritis in Pigs

    doi: 10.3390/ijms23105467

    Figure Lengend Snippet: Influence of pituitary adenylate cyclase-activating peptide (PACAP) alone ( A , C ) and PACAP receptor (PAC1R) antagonist with PACAP ( B , D ) on the contractile frequency in the myometria ( A , B ) and endometrium/myometrium ( C , D ) strips of gilts from the CON (grey bars), SAL (hatched bars) and E. coli (black bars) groups. Results were calculated for five gilts in each group. The actions of the antagonist (a dose of 10 − 6 M) and particular PACAP doses are depicted as the percentage (mean ± SEM) change from the basal (pre-treatment period) frequency, taken as 100% (horizontal lines). * p < 0.05, ** p < 0.01, *** p < 0.001 compared to the basal value in each group; A p < 0.05, AAA p < 0.001 compared between the CON and E. coli groups for the same treatment; B p < 0.05, BBB p < 0.001 compared between the SAL and E. coli groups for the same treatment; # p < 0.05, ## p < 0.01, ### p < 0.001 compared between the antagonist with PACAP action versus PACAP action alone for the same group/tissue/PACAP dose.

    Article Snippet: The strips were then treated with PAC1 receptor antagonist (dose: 10 −6 M, cat. no. 3236, Tocris) for 2 min, and PACAP (doses as given above) was then administered.

    Techniques: